46 results about "Active immunisation" patented technology

The invention provides a vaccine for immunizing poultry and other animals against infection by a gram-negative bacteria, and a method of immunizing an animal using the vaccine. The vaccine may contain purified siderophore receptor proteins derived from a single strain or species of gram-negative bacteria or other organism, which are cross-reactive with siderophores produced by two or more strains, species or genera of gram-negative bacteria. The invention further provides a process for isolating and purifying the siderophore receptor proteins, and for preparing a vaccine containing the proteins. Also provided is a method for diagnosing gram-negative sepsis.

Disclosed are pharmaceutical compositions and methods for preventing or treating a number of amyloid diseases, including Alzheimer's disease, prion diseases, familial amyloid neuropathies and the like. The pharmaceutical compositions include immunologically reactive amounts of amyloid fibril components, particularly fibril-forming peptides or proteins. Also disclosed are therapeutic compositions and methods which use immune reagents that react with such fibril components.

IgG and IgM autoantibody levels against phosphorylcholine in subjects with hypertension (diastolic pressure>95 mmHg) were determined at baseline in order to determine the importance of antibodies for the development of atherosclerosis. The results show that increases in intima-media thickness (IMT) at a follow-up four years after baseline were significantly less prevalent in subjects having high IgM autoantibodies to phosphorylcholine. The presence or absence of IgM autoantibodies against phosphorylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determine IgM antibodies toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of IgM antibodies can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate. A pharmaceutical composition comprising a phosphorylcholine conjugate (active immunization) or a monoclonal antibody with specificity to a phosphorylcholine conjugate (passive immunization) is proposed and the use of these compositions as active or passive immunogens in the treatment or prevention of atherosclerosis.

The present invention relates to an Aβ(X-38 . . . 43) oligomer having a high molecular weight, or a derivative thereof, a process for preparing the oligomer or derivative, compositions comprising the oligomer or derivative, and uses of the oligomer or derivative such as its use for treating or preventing an amyloidosis (e.g. by active immunization), for diagnosing an amyloidosis, and for providing agents that are capable of binding to the Aβ(X-38 . . . 43) oligomer or derivative. The subject invention also describes agents that are capable of binding to the Aβ(X-38 . . . 43) oligomer or derivative, e.g. antibodies, compositions comprising the agents, and uses of the agents such as their use for treating or preventing an amyloidosis (e.g. by passive immunization) and for diagnosing an amyloidosis.

The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.

If pathogen factors such as meningococcal NMB 1870 or flaviviral NS1 are able to sequester factor H in the blood then its inhibitory effect on complement may be disturbed, thereby permitting C3 to initiate a dramatic attack on host endothelial tissue. In combination with a strong inflammatory response, this attack can result in sever damage to the endothelium, with resulting hemorrhagic syndrome. Blocking the interaction between pathogen factors and factor H may thus be used to treat and/or prevent these pathogen-induced hemorrhagic syndromes. The interaction may, for instance, be blocked by antibodies, either delivered endogenously (passive immunisation) or produced by a patient's immune system (active immunisation).

The invention relates to the fields of biotechnology and medicine, and provides a modified dendritic cell (DC); a dendritic cell is infected with MG-7Ag antigen mimic epitope tandem sequences loaded with a lentivirus vector, and a target antigen sequence is integrated into a dendritic cell genome. The invention provides a rapid culture scheme of the dendritic cell derived from a peripheral blood monocyte in vitro, and also provides a vaccine with an active ingredient of the modified dendritic cell. The vaccine is used for tumor prevention and active immunotherapy. The MG-7Ag antigen sequence-modified DC vaccine can obtain high-purity CTL cells and efficient target cell killing ability after DC-CTL co-culture, and the co-culture supernatant contains high-concentration IFN[gamma] secretion.After tumor attack, the tumorigenic volume of mice in a DC-CTL group is significantly smaller than that of mice in a control group, and the DC vaccine has great potential value in immunotherapy of MG-7Ag positive tumor.

The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against A. baumannii infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against A. baumannii infection. The compositions and methods of the invention are useful for preventing or treating A. baumannii infections, including those caused by strains resistant to carbapenems and all other antibiotics except colistin or tigecycline, also referred to as extreme drug resistant (XDR) A. baumannii infections, and those resistant to every FDA approved antibiotic, also referred to as pan-drug resistant (PDR) A. baumannii infections.

The successful identification of epitope peptides specific to adenovirus belonging to subgroup B and epitope peptides exhibiting specificity to all adenoviruses using hexon proteins which exhibit the highest homology among genes of adenoviruses of various subgroups is herein described. The peptides have a function capable of efficiently inducing adenovirus-specific cytotoxic T cells (CTLs). Thus, the peptides disclosed herein find utility as vaccines for active immunization. Furthermore, CTLs induced by such peptides find utility as passive immunotherapeutic agents.

A method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER1/Human EGFR) comprising administering to a patient in need of such treatment a flexible and active regimen for combining Anaplastic Lymphoma Kinase Inhibitors (ALK Inhibitors) and anti-EGF antibodies for inhibition of the pathway activated by EGF-EGFR binding (mAb). The anti-EGF antibodies can be produced by active immunization or provided passively by the administration of antibodies that are anti-EGF. The method comprises ALK Inhibitors administered according to a continuous regimen based on an average daily dose in the range of 10 to 250 mg and the mAb is co-administered either actively or passively according to a dosing regimen achieving a therapeutic effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly.

The invention belongs to the field of medical technology, and specifically relates to an application of escherichia coli succinodehydrogenase iron-sulfur protein SdhB. According to active immunization and passive immunization tests, the escherichia coli succinodehydrogenase iron-sulfur protein SdhB and the corresponding antibody have an obvious immune protection effect on the infection of clinical pathogenic bacteria of escherichia coli. Therefore, the escherichia coli succinodehydrogenase iron-sulfur protein SdhB and the corresponding antibody can be used for preparing a medicine for preventing and treating diseases caused by the infection of clinical pathogenic bacteria of animal escherichia coli. The medicine does not generate drug resistance and can effectively prevent and treat the diseases caused by the infection of clinical pathogenic bacteria of escherichia coli.

A method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER1/Human EGFR) comprising administering to a patient in need of such treatment a flexible and active regimen for combining a tyrosine kinase inhibitor (TKI) and anti-EGF antibodies for inhibition of the pathway activated by EGF-EGFR binding (mAb). The anti-EGF antibodies can be produced by active immunization or provided passively by the administration of antibodies that are anti-EGF. The method comprises TKI administered according to a continuous regimen based on an average daily dose in the range of 10 to 150 mg and the mAb is co-administered either actively or passively according to a dosing regimen achieving a therapeutic effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly.

The invention discloses a method for improving laying rate of active immunization of fusion prolactin of a wulong goose. The method comprises the following step: (1) first strand synthesis and amplification of cRNA; (2) building, screening and identifying of a PRL prokaryotic expression vector; (3) inducible expression and crushing of a recombinant PRL protein; (4) SDS-PAGE detection and concentration determination of the recombinant PRL protein; (5) purification and recovery of the recombinant PRL protein; (6) preparation of a recombinant PRL protein injection; and (7) active immunization, observation and recording. The broodiness and the laying rate of the wulong goose can be improved, so that the production performance and the market value of the Wulong goose can be improved.

The invention discloses a tissue-factor-based tumor peptide vaccine which is AnsB-TF fusion protein formed after a sequence fragment containing epitope targets in human TF genes is expressed. The invention also discloses a preparation method and application of the tumor peptide vaccine. According to the preparation method, a TF peptide fragment containing epitope targets is connected with an AnsB carrier through a genetic engineering means so as to obtain the tumor peptide vaccine taking tissue factors as target epitopes. The vaccine obtains prevention and treatment effects on tumors through active immunization on TF epitope targets. The active immunization not only can completely block the effect of TF on tumor surfaces, but also can be used for avoiding the trouble of multi-time administration.

A method of modulating an immune response in a subject is disclosed. The invention is based on the discovery that an effective therapeutic strategy for ameliorating the inflammation-related symptoms of an immune-mediated disease, such as arthritis, can be achieved by modulation of the underlying immune response itself, rather than by merely addressing the resulting inflammation. This strategy can be used to regulate the inflammatory response and is applicable to a variety of contexts in which immune modulation is desired, such as mucosal tolerization, DNA vaccination, anergy induction, active immunization, and ex vivo modulation of antigen-specific T cells. In one embodiment, the method comprises administering to the subject a bacterial dnaJ peptide or a human homolog or a non-homologous human isoform thereof.

The invention provides a security defense method for an industrial control system network, the industrial control system network comprises a shared network module and an industrial control network module, and the security defense method comprises the following steps: establishing a management center module in the shared network module; enabling the management center module to perform security management on a plurality of grading systems in the shared network module; establishing a trusted security module communicating with the management center module in the industrial control network module;and enabling the trusted security module to perform trusted defense on the industrial control network module. The invention further provides a security defense system of the industrial control systemnetwork. According to the security defense method and system for the industrial control system network provided by the invention, the transformation of the defense method from passive 'blocking, searching and killing' to active immunization is realized, and organized attacks with clear targets can be effectively defended on the premise of meeting the requirements of high real-time performance andhigh reliability.